Anebulo Pharmaceuticals 8-K Report: Key Insights from February 20, 2025 Filing

Here are the key insights extracted from the provided section of the financial report:

1. Entity Information:

• Company Name: Anebulo Pharmaceuticals, Inc.
• CIK: 0001815974
• SEC Filing Type: 8-K
• Filing Date: February 20, 2025
• Business Address: 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734
• Contact Number: (512) 598-0931
• Stock Exchange: NASDAQ
• Ticker Symbol: ANEB
• Par Value of Common Stock: $0.001

2. Filing Context:

• Period Covered: The report is for a single day, February 20, 2025.

3. Financial Metrics:

• Currency: All amounts are reported in U.S. Dollars (USD).
• Measurement Units: Shares are referenced, indicating potential share-related disclosures in the report.

4. Additional Information:

• The report is structured using XBRL (eXtensible Business Reporting Language), which is a standard for digital business reporting.

5. Regulatory Compliance:

• The report references an XSD schema (aneb-20250220.xsd), indicating compliance with SEC reporting standards.

This information outlines the basic corporate data and compliance details relevant to investors or analysts reviewing the entity's recent financial disclosures.